目的 探討速感寧膠囊聯(lián)合磷酸奧司他韋對(duì)流行性感冒患者血清炎性因子及免疫功能的影響。方法 回顧性分析2020年2月—2021年2月在天津市寧河區(qū)醫(yī)院診治的96例流行性感冒患者臨床資料，根據(jù)用藥的差別分為對(duì)照組和治療組，每組各48例。對(duì)照組口服磷酸奧司他韋膠囊，75 mg/次，2次/d；治療組在對(duì)照組基礎(chǔ)上口服速感寧膠囊，0.9 g/次，3次/d。兩組患者均經(jīng)5 d治療。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀消失時(shí)間，及血清超敏C反應(yīng)蛋白（hs-CRP）、降鈣素原（PCT）、白細(xì)胞介素-17（IL-17）、單核細(xì)胞趨化蛋白-1（MCP-1）和巨噬細(xì)胞移動(dòng)抑制因子（MIF）水平。結(jié)果 經(jīng)治療，對(duì)照組有效率為83.33%，顯著低于治療組的97.92%（P<0.05）。經(jīng)治療，治療組臨床癥狀改善時(shí)間明顯早于對(duì)照組（P<0.05）。經(jīng)治療，兩組患者血清hs-CRP、PCT、IL-17、MCP-1、MIF水平均明顯降低，且治療組降低更明顯（P<0.05）。結(jié)論 速感寧膠囊聯(lián)合磷酸奧司他韋膠囊治療流行性感冒患者可顯著改善臨床癥狀，降低機(jī)體炎癥介質(zhì)表達(dá)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the efficacy of Suganning Capsules combined with oseltamivir phosphate in treatment of influenza and its effect on serum inflammatory factors. Methods The clinical data of 96 patients with influenza Patients in Tianjin Ninghe District Hospital from February 2020 to February 2021 were analyzed retrospectively and divided into control and treatment groups, and each group had 48 cases. Patients in the control group were po administered with Oseltamivir Phosphate Capsules, 75 mg/time, twice daily. Patients in the treatment group were po administered with Suganning Capsules, 0.9 g/time, three times daily. Patients in two groups were treated for 5 d. After treatment, the clinical efficacy was evaluated, the disappearance time of clinical symptoms, and the serological indexes of hs-CRP, PCT, IL-17, MCP-1 and MIF in two groups before and after treatment were compared. Results After treatment, the effective rate in the control group was 83.33%, which was significantly lower than 97.92% in the treatment group (P < 0.05). After treatment, the improvement time of clinical symptoms in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the serum levels of hs-CRP, PCT, IL-17, MCP-1 and MIF were significantly decreased in two groups, especially in the treatment group (P < 0.05). Conclusion Suganning Capsules combined with oseltamivir phosphate in treatment of influenza can significantly improve clinical symptoms and reduce the expression of inflammatory mediators, which has a certain clinical application value.

R974

天津市衛(wèi)生和計(jì)劃委員會(huì)課題（2015RB15401）